SAN CARLOS, Calif., August 13, 2026

Biomea Fusion, Inc. announced that the first participant has been dosed in a newly activated arm of the ongoing OPAL study evaluating icovamenib in combination with low-dose semaglutide in people with overweight or obesity without type 2 diabetes. The randomized, double-blind study arm is designed to investigate whether adding the company’s investigational oral small molecule icovamenib to semaglutide can enhance weight loss while also supporting physical function, body composition, muscle health and metabolic outcomes. The study is being conducted in collaboration with the University of Leicester, Leicester Diabetes Centre and the NIHR Biomedical Research Centre Leicester. The newly initiated arm will enroll approximately 64 participants, randomized 1:1 to receive either icovamenib plus low-dose semaglutide or low-dose semaglutide alone. Icovamenib will be administered at 100 mg once daily for 12 weeks, while semaglutide will be administered for 24 weeks. The primary endpoint will be assessed at Week 24, providing an opportunity to evaluate whether the combination can deliver benefits beyond weight reduction alone.

OPAL Study Focuses on Quality of Weight Loss

The OPAL study is designed to examine how emerging obesity treatments affect broader measures of health rather than focusing exclusively on the number of kilograms lost. Researchers will evaluate walking performance, physical function, muscle health, body composition and metabolic markers, along with patient-reported quality-of-life measures. This approach addresses an increasingly important question in obesity treatment: whether pharmacological weight loss can preserve or improve functional health and lean tissue while reducing excess fat. According to Biomea, preclinical studies of icovamenib combined with semaglutide demonstrated enhanced weight reduction driven by fat loss while preserving lean mass. The company has also reported preclinical evidence suggesting that icovamenib may influence GLP-1 receptor expression, myogenesis and adipose tissue metabolism. However, these findings remain preclinical and must be validated in human clinical studies. The new OPAL arm is therefore an important test of whether the biological effects observed in laboratory models translate into measurable benefits for people with obesity.

Icovamenib Could Expand Beyond Diabetes

Icovamenib is an orally administered investigational small molecule currently being evaluated in Phase 2 clinical development for type 1 and type 2 diabetes. Biomea is developing the compound based on its proposed ability to reversibly downmodulate menin, a transcriptional regulator involved in pancreatic beta-cell biology. Preclinical research has indicated that icovamenib may promote glucose-dependent beta-cell proliferation and enhance insulin production and secretion, supporting the company’s broader strategy of developing potential beta-cell restorative therapies. The obesity program represents an expansion of icovamenib’s potential therapeutic application into metabolic disease beyond diabetes. In the OPAL combination study, researchers will investigate whether icovamenib can complement the established weight-loss effects of semaglutide, a GLP-1 receptor agonist, while potentially addressing aspects of body composition and physical function. The scientific rationale is based primarily on preclinical findings, so the clinical study will be important in determining whether the combination produces meaningful improvements in humans.

Advertisement

cGxPJobs Banner

Clinical Study Could Provide Key Obesity Development Data

The initiation of dosing represents an important clinical development milestone for Biomea Fusion, but it does not establish that icovamenib improves obesity outcomes or that the combination is superior to semaglutide alone. The study’s randomized design should provide a clearer comparison between the combination and low-dose semaglutide monotherapy across weight, body composition, muscle and functional measures. Results from the Week 24 primary endpoint assessment could help determine whether icovamenib has a clinically meaningful role as an adjunct to GLP-1-based obesity treatment. If positive, the findings could support further development of icovamenib in obesity and strengthen the company’s broader metabolic disease strategy. At present, however, icovamenib remains investigational, and the potential benefits suggested by preclinical studies require confirmation through controlled clinical data. The OPAL study therefore represents an early but potentially important step in determining whether Biomea’s approach can improve the quality of weight loss in addition to its magnitude

Source:Biomea Fusion,press release